ROTTERDAM, the Netherlands and SAN DIEGO, Dec. 7, 2024 — SkylineDx, a leader in molecular diagnostics for various diseases, announces that new data on SKY92’s prognostic value in multiple myeloma will be presented at the upcoming American Society of Hematology (ASH) conference. This data comes from the PROMMIS real-world study, conducted across nine U.S. academic cancer centers. The presentation, led by Dr. Noa Biran, will emphasize SKY92’s significant role in multiple myeloma risk assessment.
Multiple myeloma, a complex hematological cancer, presents challenges despite advancements in treatment. High-risk patients experience poorer outcomes. While traditional methods focus on cytogenetic abnormalities, the PROMMIS study demonstrates SKY92’s independent prognostic value.
The study [1] followed 251 newly diagnosed patients for almost four years. Results indicated limited prognostic value from individual or combined chromosomal abnormalities, except for 1q21 in patients over 65. However, SKY92 was a far stronger predictor of poor outcomes, irrespective of other genetic factors.
Combining SKY92 with markers like gain(1q21) provided even more precise risk stratification. Patients identified as high-risk by both tests showed the worst prognoses, highlighting the tests’ complementary nature.
Dr. Jvalini Dwarkasing, SkylineDx’s Chief Scientific Officer, stated that SKY92 improves multiple myeloma patient care by providing a reliable method for identifying high-risk disease, enabling doctors to tailor treatments effectively. This reinforces their dedication to personalized medicine.
This study significantly advances multiple myeloma understanding and treatment. SKY92 enhances high-risk disease identification and refines the use of genetic information. Integrating this technology into standard care improves patient support.
SkylineDx acknowledges the contributions of patients, doctors, and researchers involved in the PROMMIS study.
About MMprofiler with SKY92
Multiple Myeloma is a diverse disease with varying patient outcomes. MMprofiler, using the SKY92 biomarker, enhances disease understanding. This molecular diagnostic test analyzes 92 genes in myeloma plasma cells to determine disease aggressiveness. High-risk myeloma is less responsive to standard treatments, potentially benefitting from intensified therapy. MMprofiler with SKY92 is CE-IVD registered in Europe and available as a laboratory developed test (LDT) from SkylineDx’s CAP/CLIA lab in San Diego (CA, USA).
About SkylineDx
SkylineDx is a biotechnology company specializing in molecular diagnostics for oncology, inflammatory, and infectious diseases. SkylineDx translates gene expression signatures into clinically useful diagnostic products, helping healthcare professionals determine disease type or status and predict treatment response. This allows personalized treatment approaches. SkylineDx is headquartered in Rotterdam, the Netherlands, with U.S. operations and a CAP/CLIA certified laboratory in San Diego, California, USA.
Footnotes:
- Brian et al. Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study